Publications Database

Aman M. G. et al. (2005)

Acute and long-term safety and tolerability of risperidone in children with autism.

Journal of Child and Adolescent Psychopharmacology

15(6), pp. 869-884

Read Abstract (New Window)

Arnold L. E. et al. (2003)

Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials.

Journal of the American Academy of Child and Adolescent Psychiatry

42(12), pp. 1443-1450

Read Abstract (New Window)

Campbell M. et al. (1993)

Naltrexone in autistic children: behavioral symptoms and attentional learning.

Journal of the American Academy of Child and Adolescent Psychiatry

32(6), pp. 1283-1291

Read Abstract (New Window)

Ernst M. et al. (1993)

Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children.

Psychopharmacology Bulletin

29(2), pp. 221-227

Read Abstract (New Window)

Gonzalez N. M. et al. (1994)

Naltrexone plasma levels, clinical response and effect on weight in autistic children.

Psychopharmacology Bulletin

30(2), pp. 203-208

Read Abstract (New Window)

McDougle C. J. et al. (2005)

Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology.

American Journal of Psychiatry

162(6), pp. 1142-1148

Read Abstract (New Window) Read Full (New Window)

Scahill L. et al. (2001)

Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism.

Journal of Child and Adolescent Psychopharmacology

11(4), pp. 377-388

Read Abstract (New Window)

Scahill L. et al. (2001)

Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism.

Journal of Child and Adolescent Psychopharmacology

Winter, 11(4), pp, 377-88.

Read Abstract (New Window)